Journal of Liver

Immune regulation in hepatic inflammation and injury

Christis Zenios^* Department of Liver Disease and Immunology, Near East University Hospital, Nicosia, Cyprus
^*Correspondence: Christis Zenios, Department of Liver Disease and Immunology, Near East University Hospital, Nicosia, Cyprus, Email:

Received: 28-Nov-2025, Manuscript No. JLR-25-30474; Editor assigned: 01-Dec-2025, Pre QC No. JLR-25-30474 (PQ); Reviewed: 15-Dec-2025, QC No. JLR-25-30474; Revised: 22-Dec-2025, Manuscript No. JLR-25-30474 (R); Published: 29-Dec-2025, DOI: 10.35248/2167-0889.25.14.278

Description

Inflammatory liver diseases represent a spectrum of conditions characterized by immune-mediated damage to hepatocytes, bile ducts, and vascular structures within the liver. These disorders include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and various forms of viral and toxin-induced hepatitis. The immune system plays a dual role in liver health, both protecting against pathogens and contributing to tissue injury when regulation is insufficient. Among the cellular components involved in maintaining immune balance, Regulatory T cells (Tregs) have emerged as significant modulators of hepatic inflammation and immune homeostasis.

Primary biliary cholangitis involves chronic immune-mediated destruction of intrahepatic bile ducts, leading to cholestasis and eventual fibrosis. Tregs in this setting are important for preventing excessive immune-mediated ductal injury. Evidence suggests that patients with progressive disease may exhibit alterations in Treg number or function, resulting in insufficient suppression of autoreactive T cells and persistent inflammation. Experimental approaches aiming to enhance Treg activity, including cytokine-mediated expansion, have demonstrated reduced bile duct injury and slower disease progression in preclinical studies.

Primary sclerosing cholangitis, a condition marked by chronic inflammation and fibrosis of the bile ducts, also involves dysregulation of Treg-mediated control. The hepatic environment in this disease is characterized by persistent activation of effector T cells, natural killer cells and other immune components that contribute to bile duct destruction and progressive fibrosis. While the precise mechanisms underlying Treg dysfunction are not fully elucidated, studies indicate that the inflammatory milieu and alterations in chemokine signaling may impair Treg migration, survival, or suppressive activity within the liver.

Viral hepatitis represents another scenario in which Tregs play a significant role. Both hepatitis B and hepatitis C infections elicit strong immune responses aimed at clearing infected hepatocytes. While effector T cells are necessary for viral control, excessive activation can result in liver injury. Tregs help modulate this response, reducing collateral tissue damage without completely inhibiting antiviral immunity. However, in chronic infections, high levels of Tregs can suppress effective antiviral responses, contributing to viral persistence. This dual effect highlights the complex role of Tregs in balancing protective immunity and tissue preservation.

Alterations in Treg populations have been observed in various experimental models of liver injury. In chemical-induced hepatitis or toxin-mediated liver injury, depletion of Tregs exacerbates hepatic inflammation and increases hepatocyte apoptosis. Conversely, adoptive transfer of Tregs or induction of their expansion mitigates liver damage, decreases serum markers of hepatocellular injury and improves survival. These findings underscore the protective function of Tregs in controlling immune-mediated damage and suggest potential avenues for therapeutic intervention.

Another limitation is the variability in Treg populations between individuals. Genetic factors, environmental exposures and the presence of ongoing inflammation can influence Treg number, function and stability. In autoimmune liver diseases, heterogeneity in Treg dysfunction contributes to differences in disease severity and treatment response. Standardized methods for measuring and manipulating Tregs are still being refined and clinical trials must consider patient-specific variability in designing therapeutic protocols.

Long-term outcomes of Treg modulation in liver disease are still being evaluated. Early studies demonstrate improvements in biochemical markers of liver injury, histological evidence of reduced inflammation and decreased fibrosis in experimental models. Clinical studies are more limited but suggest that therapies designed to expand or support Tregs can reduce disease activity in autoimmune hepatitis and mitigate immunemediated injury in transplant settings. Further investigation is needed to assess the durability of these effects, potential longterm adverse outcomes and the impact on patient survival and quality of life.

In conclusion, Tregs play an integral role in controlling inflammation, maintaining immune balance and supporting tissue repair in the liver. Dysregulation of Tregs contributes to the development and progression of autoimmune, cholestatic and virus-mediated liver diseases. Therapeutic approaches aimed at enhancing Treg number or function offer opportunities to reduce hepatic inflammation and tissue injury. Nevertheless, careful consideration of potential risks, including impaired antiviral responses and increased susceptibility to infection, is necessary. Continued research into the biology, regulation and therapeutic modulation of Tregs will provide valuable insights for the management of inflammatory liver disorders and may improve long-term outcomes for affected patients.